Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
A6NK06

UPID:
IRG1_HUMAN

ALTERNATIVE NAMES:
Aconitate decarboxylase; Aconitate decarboxylase 1; Cis-aconitic acid decarboxylase; Immune-responsive gene 1 protein

ALTERNATIVE UPACC:
A6NK06

BACKGROUND:
The protein Cis-aconitate decarboxylase, also referred to as Aconitate decarboxylase 1, plays a critical role in the body's defense mechanisms. It is involved in producing itaconate, a compound that inhibits inflammation and supports the immune system's fight against infections. The protein's function in generating a metabolic state that suppresses viral replication further underscores its significance in antiviral defense.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Cis-aconitate decarboxylase offers promising avenues for therapeutic intervention. Its key role in controlling inflammation and enhancing the immune system's antimicrobial and antiviral capabilities makes it a valuable target for drug discovery efforts aimed at treating a wide range of diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.